Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PLAUR encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. Additionally we are shipping PLAUR Kits (52) and PLAUR Proteins (30) and many more products for this protein.
Showing 10 out of 163 products:
Human Polyclonal PLAUR Primary Antibody for WB - ABIN1944762
Roldan, Cubellis, Masucci, Behrendt, Lund, Danø, Appella, Blasi: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. in The EMBO journal 1990
Show all 5 references for ABIN1944762
Human Monoclonal PLAUR Primary Antibody for FACS - ABIN2664853
Beaufort, Leduc, Rousselle, Magdolen, Luther, Namane, Chignard, Pidard: Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. in Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 4 references for ABIN2664853
Human Monoclonal PLAUR Primary Antibody for FACS - ABIN2663624
Tarui, Mazar, Cines, Takada: Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction. in The Journal of biological chemistry 2001
Show all 4 references for ABIN2663624
Rat (Rattus) Polyclonal PLAUR Primary Antibody for WB - ABIN223401
Viswanathan, Richardson, Togonu-Bickersteth, Dai, Liu, Vatsya, Sun, Yu, Munuswamy-Ramanujam, Baker, Lucas: Myxoma viral serpin, Serp-1, inhibits human monocyte adhesion through regulation of actin-binding protein filamin B. in Journal of leukocyte biology 2009
Significance of the urokinase-type plasminogen activator (show PLAU Antibodies) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (show NPHS1 Antibodies) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an (show EPHA3 Antibodies)in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals incre (show PTEN Antibodies)ased the impaired angiogeni (show AKT1 Antibodies)c phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
uPAR contributes to macrophage driven atherosclerotic lesion formation.
we have firstly shown a fundamental mechanism of urokinase system(uPa (show PLAU Antibodies) and uPAR)-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
our data show that uPAR is required for efficient skin tumor formation
Tumours with high levels of uPAR, as well as cells invading leiomyoma tissue with up-regulated uPAR expression, all displayed enhanced activity of gelatinolytic enzymes.
deficiency of uPAR and PSMD6 (show PSMD6 Antibodies) delays DNA repair and leads to decreased cell survival.
beta-elemene downregulates expression of uPA (show PLAU Antibodies), uPAR, MMP-2 (show MMP2 Antibodies), and MMP-9 (show MMP9 Antibodies) in a murine intraocular melanoma model
Soluble urokinase plasminogen (show PLG Antibodies) activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease
we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members
Report presence of urokinase-type plasminogen activator receptor in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of male accessory gland inflammation.
uPAR expression is higher in normal pregnant women than that in patients with threatened abortion. uPAR promotes trophoblast migration and invasion during embryo implantation as well as plays a role in trophoblast differentiation into syntrophoblasts.
This study examines the complexes of PAI-1 (show SERPINE1 Antibodies) with tissue-type and urokinase-type plasminogen activator (show PLAU Antibodies) and vitronectin (show VTN Antibodies) revealed by changes in the conformation and dynamics of the reactive center loop.
results show that cleaved uPAR forms are significantly increased in patients with advanced prostate cancer.
Hypoxia enhanced the endogenous uPAR mRNA and protein expression.HIF-1 protein bound the putative HIF-1 (show HIF1A Antibodies) response element on the uPAR promoter.uPAR protein expression was detected in cervical cancer but not in normal cervix or CIN (show PDXP Antibodies).
uPAR/suPAR is elevated in most kidney diseases.
The present paper develops a mathematical model of cancer recurrence besed on UPAR serum concentration.
Data show that urokinase-type plasminogen activator (uPA (show PLAU Antibodies)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (show PLAU Antibodies) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (show PLAU Antibodies)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA (show PLAU Antibodies) activity and RNA expression of u-PA (show PLAU Antibodies) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (show IGF2R Antibodies) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (show IGF2R Antibodies) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3